NEW YORK (GenomeWeb News) - Third Wave Technologies said today that it will collaborate with Laboratory Corporation of America to develop a diagnostic that may be used in conjunction with a heart failure drug that is being developed by Arca Discovery. 
 
The diagnostic is intended to help physicians determine use of the drug bucindolol, a beta blocker that Third Wave said could be "the first genetically targeted cardiovascular drug."
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

Futurism writes that gene doping could be the next generation of cheating in sports.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.